[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lower-respiratory-tract-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lower-respiratory-tract-infection":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,79,103,133,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100347835","phase-3-phase-iii-das181-lower-tract-piv-infection-in-immunocompromised-subjects-substudy-das181-for-covid-19-rct-study-100347835",false,"NCT03808922","Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects","Inclusion Criteria:\n\n1. At the time of randomization, requires supplemental oxygen ≥2 LPM due to hypoxemia.\n2. Immunocompromised, as defined by one or more of the following:\n\n   * Received an autologous or allogeneic hematopoietic stem cell transplantation (HSCT) at any time in the past\n   * Received a solid organ transplant at any time in the past\n   * Has been or is currently being treated with chemotherapy for hematologic malignancies (e.g., leukemia, myeloma, lymphoma) and\u002For solid tumor malignancies (e.g., lung, breast, brain cancer) at any time in the past\n   * Has an immunodeficiency due to congenital abnormality (only applicable to subjects age \\\u003C 18 years old) or pre-term birth (only applicable to subjects age ≤ 2 years old)\n3. Has, within 3 days prior to randomization, a confirmed LRTI with a sialic acid dependent respiratory virus\n4. If female, subject must meet one of the following conditions:\n\n   * Not be of childbearing potential or\n   * Be of childbearing potential and have a negative urine\u002Fserum pregnancy test and agrees to practice an acceptable method of contraception\n5. Non-vasectomized males are required to practice effective birth control methods\n6. Capable of understanding and complying with procedures as outlined in the protocol\n7. Provides signed informed consent prior to the initiation of any screening or study-specific procedures\n\nFor COVID-19 sub study:\n\n1. Be ≥18 years of age\n2. Provide adequate medical history to permit accurate stratification (but health status may be healthy, high-risk conditions, or immunocompromised).\n3. Prior to SARS CoV 2 infection, has the ability to carry out self-care activities of daily living (basic ADL)\n4. Have lower respiratory tract infection (LRTI) confirmed by CT imaging, with or without contrast, to involve at least 2 lobes of the lung.\n5. Has laboratory-confirmation of the presence of SARS CoV 2 in the respiratory tract by at least one of the following samples\n6. Satisfy inclusion criteria #1, 4, 5, 6, 7 of the main study\n\nExclusion Criteria:\n\n1. Subjects may not be on hospice care or, in the opinion of the investigator, have a low chance of survival during the first 10 days of treatment\n2. Subjects with Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), or Alkaline Phosphatase (ALP) ≥3x ULN and Total Bilirubin (TBILI) ≥2x ULN Note: Subjects with ALT\u002FAST\u002FALP ≥ 3x ULN AND TB ≥2x ULN that have been chronically stable (for \\>1 year on more than one assessments) due to known liver pathology including malignancy (primary or metastasis), chronic medications, transplantation, or chronic infection will not be excluded\n3. Female subjects breastfeeding or planning to breastfeed at any time through 30 days after the last dose of study drug\n4. Subjects taking any other investigational drug used to treat pulmonary infection.\n5. Psychiatric or cognitive illness or recreational drug\u002Falcohol use that, in the opinion of the principal investigator, would affect subject safety and\u002For compliance\n6. Subjects with known hypersensitivity to DAS181 and\u002For any of its components\n7. Subjects with severe sepsis due to either their baseline SAD-RV infection or a concurrent viral, bacterial, or fungal infection and meet at least one of the following criteria:\n\n   * Has evidence of vital organ failure outside of the lung (e.g., liver, kidney)\n   * Requires vasopressors to maintain blood pressure\n\nFor COVID-19 sub study:\n\n1. Subjects requiring invasive mechanical, Bi-PAP or CPAP ventilation at randomization.\n2. Subjects receiving any other investigational or empiric treatment for SARS-2-CoV (either as part of a clinical trial or under emergency approval (approved agents for the management of symptoms, e.g., fever, are permitted).\n3. Subjects who are known HIV-positive (and not undetectable at most recent HIV RNA assessment)\n4. Subjects who are currently taking immunomodulating biologics (e.g, interferons, interleukin)\n5. Subjects with severe sepsis due to either their SARS-CoV-2 infection or a concurrent viral, bacterial, or fungal infection and meeting at least one of the following criteria:\n\n   * Have evidence of vital organ failure outside of the lung (e.g., liver, kidney)\n   * Require vasopressors to maintain blood pressure\n6. Subjects meeting exclusion criteria #2, 3, 5 and 6 of the main study","ALL",{"count":18,"type":19},274,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.\n\nIt also contains a sub-study to enroll patients with severe COVID-19.",[25,26,27,28],"Lower Respiratory Tract Infection","Parainfluenza","Immunocompromised","COVID-19",[26,30,27,25,31,32,33,34,35],"PIV","LRTI","COVID19","SARS-CoV-2","Coronavirus","Ansun","RECRUITING","2026-06-18",{"date":39,"type":40},"2026-06-23","ACTUAL",{"date":42,"type":40},"2019-05-23",{"date":44,"type":19},"2028-09-01",{"name":46,"class":47},"Ansun Biopharma, Inc.","INDUSTRY",28,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":20,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100576653","reducing-overuse-of-antibiotics-with-decision-support-100576653","NCT06788093","Reducing Overuse of Antibiotics With Decision Support","Reducing Overuse of Antibiotics With Decision Support in Lower Respiratory Tract Infections","ROADS","Inclusion Criteria:\n\n1. ED encounter or admission to an inpatient hospital team.\n2. EHR-based positive screen for suspected LRTI, defined as a qualifying chief complaint (e.g., cough, shortness of breath, etc.), plus triage documentation of abnormal respiratory effort and\u002For cough.\n\nExclusion Criteria: None","6 Months","17 Years",{"count":60,"type":19},2800,[62],"NA","Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia.\n\nTo address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available.\n\nClinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.",[25,65,66,67],"Pneumonia","Asthma","Bronchiolitis, Viral","2026-01-19",{"date":70,"type":40},"2026-01-22",{"date":72,"type":40},"2024-11-12",{"date":74,"type":19},"2027-04",{"name":76,"class":77},"Vanderbilt University Medical Center","OTHER",3,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":20,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100497827","the-impact-of-memed-bv-on-management-of-patients-with-suspected-lower-respiratory-tract-infections-lrti-in-the-emergency-department-ed-and-urgent-care-center-ucc-jupiter-trial-100497827","NCT05762302","The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) (\"JUPITER\" TRIAL)","A Multicenter Randomized Controlled Trial to Establish the Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) (\"JUPITER\" TRIAL)","INCLUSION CRITERIA\n\n* Patients eligible for inclusion are required to fulfill all of the following criteria:\n* Written informed consent must be obtained from the patient or his\u002Fher legal guardian.\n* 18 years of age or older.\n* Current disease duration ≤ 7 days.\n* Tactile fever or measured temperature ≥ 37.8°C (100°F) (any body site, any measurement device, including self-reported), either of them noted at least once within the last 7 days.\n* Clinical suspicion of bacterial or viral LRTI: At least one of the following respiratory signs or symptoms: cough (new or worsening), sputum production, dyspnea\u002Fshortness of breath, auscultatory abnormality (e.g. wheezing, rhonchi).\n* Clinician intent to prescribe antibiotics based on the currently available data.\n\nEXCLUSION CRITERIA\n\nPatients fulfilling any of the following criteria are not eligible for inclusion in the infectious cohort:\n\n* Systemic antibiotics within 72 hours prior to enrollment\n* Inflammatory disease (e.g., IBD, SLE, Rheumatoid arthritis, Kawasaki, other vasculitis)\n* Congenital immune deficiency (CID)\n* A proven or suspected infection on presentation with Mycobacterial (e.g., MAC, MABC), parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen\n* HIV, HBV, or HCV infection (self-declared or known from medical records)\n* Major surgery, trauma and\\\\or burns in the last 7 days\n* Pregnancy- self reported or medically confirmed\n* Active malignancy - Cancer diagnosed within the previous six months, recurrent, regionally advanced or metastatic cancer, cancer for which treatment had been administered within six months, or hematological cancer that is not in complete remission.\n* Patients with severe illnesses that affect life expectancy and quality of life such as end stage renal disease, end stage liver disease or severe COPD.\n* Clinician intent to hospitalize patient.\n* Patients with suspected concomitant infections (e.g. UTI, cellulitis, gastroenteritis, etc.)\n* Active treatment with immune-suppressive or immune-modulating therapies, including without limitations:\n\nAdministration of PO\\\\IV\\\\IM high dose steroids \\>1mg\u002Fkg\u002Fday prednisone (or equivalent) at some point in the past 10 days or daily continuous use of steroids \\> 0.25 mg\u002Fkg\u002Fday in the past 7 days Monoclonal antibodies, anti-TNF agents Intravenous immunoglobulin (IVIG) Cyclosporine, Cyclophosphamide, Tacrolimus, Azathioprine, Methotrexate G\u002FGM-CSF, Interferons\n\n•Considered unsuitable for the study by the study team","18 Years","99 Years",{"count":89,"type":19},1316,[62],"This is a Prospective, multi-center study enrolling adults subjects presented to the ED\u002FUrgent care, with symptoms consistent with lower respiratory infection (LRTI).\n\nThe reason of this study is to demonstrate the MeMed BV can help clinicians make decisions about using antibiotics in patients with lower respiratory track infections and see how it would impact clinical outcomes, antibiotics use, hospitalizations, ED clinicians find ways to improve health and medical care.",[25],"2026-01-18",{"date":95,"type":40},"2026-01-21",{"date":97,"type":40},"2023-01-31",{"date":99,"type":19},"2026-02-28",{"name":101,"class":47},"MeMed Diagnostics Ltd.",10,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100614444","clinical-predictors-of-severity-in-pediatric-community-acquired-pneumonia-at-assiut-university-childrens-hospital-100614444","NCT07279675","Clinical Predictors of Severity in Pediatric Community-Acquired Pneumonia at Assiut University Children's Hospital","CAP-Severity","Inclusion Criteria:\n\n* Children aged 1 month to 5 years.\n* Children of both sexes\n* Onset of illness in the community, not more than 48 hours after hospital admission.\n\nExclusion Criteria:\n\n* Children below 1 month, as neonatal pneumonia differs in pathology and management from CAP.\n* Children with hospital-acquired pneumonia\n* Known primary or secondary immunodeficiency\n* Children with chronic respiratory diseases (as cystic fibrosis, bronchiectasis) or congenital lung malformations.","1 Month","5 Years",{"count":113,"type":19},67,"OBSERVATIONAL","This study aims to identify the clinical factors that predict the severity of community-acquired pneumonia (CAP) in pediatric patients. Children admitted to Assiut University Children's Hospital with a diagnosis of CAP will be evaluated through clinical examination, vital signs, laboratory investigations, and radiological findings. The study focuses on determining which clinical features are associated with more severe disease, higher need for oxygen therapy, intensive care admission, or complications. Understanding these predictors may help clinicians recognize severe cases earlier and improve patient management and outcomes.",[117,118,25],"Community-Acquired Pneumonia","Pediatric Pneumonia",[120,121,122],"Community-acquired pneumonia","Clinical risk factors","Hypoxemia","NOT_YET_RECRUITING","2025-12-10",{"date":126,"type":40},"2025-12-12",{"date":128,"type":19},"2025-12-01",{"date":130,"type":19},"2027-01-01",{"name":132,"class":77},"Assiut University",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":140,"maxAge":86,"enrollmentInfo":141,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100560912","recurrent-pneumonia-in-children-100560912","NCT06583317","Recurrent Pneumonia in Children","Recurrent Pneumonia in Children at Assiut University Children's Hospital","Inclusion Criteria:\n\n* • All children more than 1 month and less than 18 years of age\n\n  * All cases presented by picture of recurrent pneumonia in the form of as at least two episodes of pneumonia in one year or three episodes ever, with radiographic clearing of densities in between.\n\nExclusion Criteria:\n\n* • All children less than 1 month and more than 18 years\n\n  * Evidence of malignancies\n  * Evidence of congenital immune deficiency\n  * Cases refusing to participate in research.\n  * Cases missed for follow up.","30 Days",{"count":142,"type":19},53,"This study aimed to analyses the clinical characteristics, risk factors and underlying causes as predictors of recurrent pneumonia in children attending AUCH",[65,25,145],"Chest Infection","2024-09-01",{"date":148,"type":40},"2024-09-04",{"date":150,"type":19},"2025-01-01",{"date":152,"type":19},"2026-01",{"name":132,"class":77},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":177,"locationsCount":4},"100538750","crp-and-lung-ultrasound-in-respiratory-evaluation-100538750","NCT06294899","CRP and Lung Ultrasound in Respiratory Evaluation","Evaluation of Point-of-Care Ultrasound Along With C-Reactive Protein-Point of Care Tests Impact on Clinical Decision-making and Perceived Usefulness in Routine Healthcare Use in Patients With Lower Respiratory Tract Infection. Correlation Between C-Reactive Protein Concentrations and Lung Ultrasound Findings.","PLURE","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Clinical suspicion of LRTI defined as acute illness lasting less than 21 days, with cough as the main symptom, accompanied by at least one other lower respiratory symptom (such as sputum production, dyspnoea, difficult breathing, or chest pain) without any other explanation for the clinical picture.\n* Ability to read, understand and willingness to give written consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients who have been treated with antibiotics during the last 14 days up to inclusion.\n* Patients with hemodynamic instability or that need emergency medical care due to the current clinical condition.\n* Previous diagnosis of lung or pleural cancer.\n* Thoracic surgery within the past 60 days.\n* Lung interstitial diseases.\n* Patients who refuse to participate in the study",{"count":163,"type":19},202,"Lower respiratory tract infections (LRTIs) are one of the most common reasons for consultation in Primary Care centres. Differentiating between viral and bacterial aetiologies can be challenging, leading to inappropriate antibiotic prescribing. Lung ultrasound (LUS), an imaging test that gained particular relevance since the beginning of the SARS-CoV-2 pandemic, offers several advantages over the classic chest X-ray in detecting and monitoring LRTIs, especially when pleural involvement exists.\n\nThis study aims to correlate LUS findings with capillary blood C-Reactive Protein (CRP) values in patients with LRTIs, evaluating LUS as a diagnostic tool and its impact on therapeutic decisions. The descriptive observational study, conducted from January 2024 to December 2026 in Lleida, will include LRTI patients attending Primary Care centres. By validating LUS as a rapid and non-invasive diagnostic tool, unnecessary antibiotic prescriptions can be reduced, promoting LUS as a complementary test in Primary Care consultations. This will facilitate appropriate diagnosis and treatment decisions for patients with LRTIs, enhancing the overall management of respiratory infections.",[166,25],"Primary Health Care",[168,169,170],"C-Reactive Protein","Lung ultrasonography","Lower Respiratory Tract Infections","2024-04-29",{"date":173,"type":40},"2024-04-30",{"date":175,"type":19},"2024-06-01",{"date":44,"type":19},{"name":178,"class":77},"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina"]